AI
Monday, October 19, 2009 11:11:05 PM
Peregrine is at $3.40 per share moving up on news of Dr. Robert Garnick joining Peregrine as Head of Regulatory Affairs.
With twenty-four years experience and a senior vice president of regulatory, quality and compliance at Genentech, Dr. Garnick was responsible for the approval of 17 products including Rituxan, Herceptin, Avastin and Lucentis.
All three bavi phase 2 cancer trials are now fully enrolled. Now we wait as survival data develops. Objective responses were stellar in all three trials exceeding Avastin responses in all cases.
Safety has been great with bavi too. Avastin has been really horrible safety-wise including, but not limited to the development of holes in the stomach, small intestine, or large intestine, severe bleeding, or death.
Peregrine has also recently brought in cancer researcher Dr. Bruce Chabner as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical director of Massachusetts General Hospital (MGH) Cancer Center, chief of hematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before coming to MGH, Dr. Chabner had a distinguished 25-year career at the National Cancer Institute (NCI), including serving as scientific director and director of the Division of Cancer Treatment.
These are two world class scientists whose expertise is focused on clinical trial design, implementation and successful completion. Their coming to Peregrine Pharmaceuticals at this point in time is another indicator that the company is at a threshold of expanded growth.
Peregrine is at an inflection point. We are at the end of three separate phase 2 cancer trials that will provide the first look at expanded numbers of patients with respect to safety and efficacy. We have already seen some superb results with bavituximab in these combination cancer trials. Now all three trials have finished enrolling. This is the statistical point where the value of a successfully advancing drug candidate soars with respect to partnering or buyout.
Here is a chart from the journal,Nature: “Avoiding Premature Licensing” that shows the inflection point with respect to stages of clinical trial phase development.
http://www.nature.com/nrd/journal/v5/n12/full/nrd2203.html
I’m really happy with the progress, and a price structure that begins to make the stock accessible to an expanded group of investors.
sunstar
With twenty-four years experience and a senior vice president of regulatory, quality and compliance at Genentech, Dr. Garnick was responsible for the approval of 17 products including Rituxan, Herceptin, Avastin and Lucentis.
All three bavi phase 2 cancer trials are now fully enrolled. Now we wait as survival data develops. Objective responses were stellar in all three trials exceeding Avastin responses in all cases.
Safety has been great with bavi too. Avastin has been really horrible safety-wise including, but not limited to the development of holes in the stomach, small intestine, or large intestine, severe bleeding, or death.
Peregrine has also recently brought in cancer researcher Dr. Bruce Chabner as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical director of Massachusetts General Hospital (MGH) Cancer Center, chief of hematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before coming to MGH, Dr. Chabner had a distinguished 25-year career at the National Cancer Institute (NCI), including serving as scientific director and director of the Division of Cancer Treatment.
These are two world class scientists whose expertise is focused on clinical trial design, implementation and successful completion. Their coming to Peregrine Pharmaceuticals at this point in time is another indicator that the company is at a threshold of expanded growth.
Peregrine is at an inflection point. We are at the end of three separate phase 2 cancer trials that will provide the first look at expanded numbers of patients with respect to safety and efficacy. We have already seen some superb results with bavituximab in these combination cancer trials. Now all three trials have finished enrolling. This is the statistical point where the value of a successfully advancing drug candidate soars with respect to partnering or buyout.
Here is a chart from the journal,Nature: “Avoiding Premature Licensing” that shows the inflection point with respect to stages of clinical trial phase development.
http://www.nature.com/nrd/journal/v5/n12/full/nrd2203.html
I’m really happy with the progress, and a price structure that begins to make the stock accessible to an expanded group of investors.
sunstar
